caa a22 4500 445332832 CHVBK 20180317142743.0 cr unu---uuuuu 170323e20110101xx s 000 0 eng 10.1245/s10434-010-1171-4 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1171-4 Consequences of Axillary Ultrasound in Patients with T2 or Greater Invasive Breast Cancers [Elektronische Daten] [M. Lee, Jennifer Eatrides, Alec Chau, Gang Han, John Kiluk, Nazanin Khakpour, Charles Cox, W. Carter, Christine Laronga] Background: Axillary ultrasound (AUS) with needle biopsy is used to detect metastasis in patients with invasive breast cancers. Our hypothesis is that preoperative AUS significantly reduces sentinel node biopsy (SLNB) use in patients with invasive breast tumors >2cm upon clinical examination. Methods: A single-institution database of patients with breast cancer and AUS was reviewed. Patients with incomplete records, clinical tumor <2cm, or postoperative AUS were excluded. A control cohort of non-AUS patients with clinical T2 (cT2) or greater disease was identified. Clinicopathologic data were collected. Simple Kappa coefficient and chi-square statistical analyses were performed. Results: AUS was performed in 153 patients vs. 370 controls. Of AUS patients, 112 (73.2%) had cT2 disease vs. 272 (73.5%) controls. Median AUS patient age was 53.7 (range, 22.8-85.8) years vs. 53.8 (range, 26.7-91.6) years; median pathologic tumor was 3.8 (range, 1.0-20.0) cm in AUS patients vs. 2.5 (range, 0.1-11.0) cm. Among AUS patients, 78% had needle biopsy; 85 of 120 (70.8%) were positive. Sixty-eight patients had SLNB: 33 after negative AUS and 35 after negative needle biopsy. Twenty-three SLNB (37.3%) were positive; 15 of 33 after negative AUS and 8 of 35 after a negative needle biopsy. Axillary dissection was performed in 102 of 153 vs. 225 of 370 controls. Sensitivity and specificity of AUS was 86.2% and 40.5%. Sensitivity of AUS plus needle biopsy was 89.3% with 100% specificity. Neoadjuvant chemotherapy was given to 49.7% of AUS patients. AUS reduced costs by more than $4,000 per patient. Conclusions: AUS reduces SLNB use and affects treatment in patients with cT2 or greater breast cancer. Routine AUS should be considered in this population. Society of Surgical Oncology, 2010 Lee M. Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL, USA aut Eatrides Jennifer University of South Florida College of Medicine, Tampa, FL, USA aut Chau Alec Division of Breast Imaging, Moffitt Cancer Center, Tampa, FL, USA aut Han Gang Biostatistics Core, Moffitt Cancer Center, Tampa, FL, USA aut Kiluk John Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL, USA aut Khakpour Nazanin Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL, USA aut Cox Charles Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL, USA aut Carter W. Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL, USA aut Laronga Christine Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL, USA aut Annals of Surgical Oncology Springer-Verlag 18/1(2011-01-01), 72-77 1068-9265 18:1<72 2011 18 10434 https://doi.org/10.1245/s10434-010-1171-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1171-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lee M. Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 700 1- Eatrides Jennifer University of South Florida College of Medicine, Tampa, FL, USA aut NATIONALLICENCE 700 1- Chau Alec Division of Breast Imaging, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 700 1- Han Gang Biostatistics Core, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 700 1- Kiluk John Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 700 1- Khakpour Nazanin Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 700 1- Cox Charles Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 700 1- Carter W. Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 700 1- Laronga Christine Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL, USA aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/1(2011-01-01), 72-77 1068-9265 18:1<72 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer